ADC Therapeutics (ADCT) Intangibles (2019 - 2022)

ADC Therapeutics has disclosed Intangibles across 4 years of filings, most recently posting $14.4 million for Q4 2022.

• Intangibles for Q4 2022 came in at $14.4 million, up 5.73% year-over-year; the trailing twelve-month figure through Dec 2022 was $14.4 million (up 5.73% YoY), and the FY2022 annual result was $14.4 million, up 5.73% from the prior year.
• Intangibles came in at $14.4 million for Q4 2022 at ADC Therapeutics, up from $13.6 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $14.4 million in Q4 2022 to a low of -$934000.0 in Q4 2019.
• The 4-year median for Intangibles is $12.4 million (2020), against an average of $9.6 million.
• Across the five-year window, Intangibles jumped 1311.13% in 2020 and increased 5.73% in 2022, its largest moves.
• ADC Therapeutics' Intangibles stood at -$934000.0 in 2019, then surged by 1311.13% to $11.3 million in 2020, then rose by 20.07% to $13.6 million in 2021, then grew by 5.73% to $14.4 million in 2022.
• The last three Intangibles figures came in at $14.4 million (Q4 2022), $13.6 million (Q4 2021), and $11.3 million (Q4 2020), per Business Quant data.